Although rejection rates and short-term graft survival have significantly improved in kidney transplantation with the introduction of calcineurin inhibitor (CNI), cardiovascular disease (CVD) and metabolic complications are being increasingly recognized as important causes of morbidity and mortality. We hypothesize that non-CNI proliferation signal inhibitor (PSI)-based immunosuppressive regimen is associated with improved arterial stiffness after kidney transplantation compared with CNI-based immunosuppressive regimens.
Renal transplantation confers a significant survival advantage in patients with end-stage kidney disease. 1 Although rejection rates and short-term graft survival have significantly improved since 1985, attributed to the introduction of calcineurininhibitors (CNIs), longer-term graft and patient survival have remained essentially unchanged. 2 Cardiovascular disease (CVD)-related mortality remains an important cause of death with functioning graft, and death with functioning graft accounts for up to 50% of late graft loss in renal transplant (RT) recipients. 3 CNIs, including cyclosporin and tacrolimus, have been associated with an increased risk of hypertension, dyslipidaemia, and diabetes, all of which may contribute to a greater risk of CVD-related mortality in RT recipients. 4 Over the last decade, studies evaluating proliferative signal inhibitors (PSIs), including sirolimus and everolimus, have demonstrated that RT recipients who made an early switch from CNI to PSI had significant improvement in 1-year graft function compared with recipients remaining on CNI. 5, 6 There have been a few observational and randomized controlled studies in RT recipients that have demonstrated that the conversion from CNI to PSI may be associated with improved cardiovascular parameters, including reduction of left ventricular mass index, stabilization of pulse wave velocity (PWV), and reduction in proinflammatory T-helper 1 cytokine levels, but it remains unclear whether this was directly attributed to the effect of PSI or as a result of CNI withdrawal and/or improvement in renal allograft function. [7] [8] [9] [10] However, the effect of PSI on glucose regulation remains unclear, and registry studies have suggested that RT recipients maintained on PSI may be at a higher risk of developing abnormal glucose regulation. 11 We hypothesize that a non-CNI PSI-based immunosuppressive regimen is associated with improved arterial stiffness after kidney transplantation compared with a CNI-based immunosuppressive regimen, independent of traditional CVD risk factors, including hypertension and dyslipidaemia. The aim of this nonrandomized, observational study was to examine the difference between RT recipients maintained on CNI and RT recipients mainted on a non-CNI PSI immunosuppressive regimen in arterial stiffness (i.e., PWV -primary endpoint) and other surrogate hemodynamic, inflammatory, and metabolic markers of CVD (secondary endpoints).
Methods
We conducted a single-center, prospective, nonrandomized, observational study of RT recipients of kidneys from live or deceased donors at Sir Charles Gairdner Hospital between June 2008 and December 2010. Eligible subjects for the study were either RT recipients initiated and maintained on a CNI-based immunosuppressive regimen for 15 months after kidney transplantation (n = 50, CNI-CNI group) or RT recipients initiated on a CNI-based immunosuppressive regimen but switched to a non-CNI PSI-based regimen within 12 months and then remaining on a PSI-based regimen until 15 months after transplant (n = 17, CNI-PSI group). Recipients receiving multiple organ grafts (n = 5), those initiated on CNI and/or prednisolone-free immunosuppressive regimen (n = 2), those switched from CNI to PSI >12 months posttransplant (n = 5) and those with atrial arrhythmias (n = 5) were excluded. All recipients were also maintained on mycophenolic acid and corticosteroids. Sir Charles Gairdner Hospital ethics committee approved the study, and written informed consent was obtained from all recipients.
Of the 17 RT recipients in the CNI-PSI group, 12 and 5 were switched from CNI (10 from cyclosporine and 7 from tacrolimus) to sirolimus and everolimus, respectively. The median time of change from CNI to PSI was 5 months posttransplant (range = 3-11 months), and all had protocol kidney biopsy before the change to exclude rejection. All were reactive conversions resulting from suboptimal graft function (as deemed by the clinicians, and all had an estimated glomerular filtration (eGFR) rate of <40 ml/min at time of change) and/or recurrent skin cancers. Of the 50 CNI recipients, 39 and 11 recipients were initiated and maintained on tacrolimus and cyclosporine, respectively. All recipients in the CNI-CNI and CNI-PSI groups had remained on the same CNI or PSI, respectively, for 15 months posttransplant.
data collection
Data was collected at 3 months (baseline) and at 15 months posttransplant. Recorded baseline data included donors' characteristics, including age, sex, and donor type (live or deceased donor) and recipients' characteristics, including age, body mass index (BMI), sex, diabetes mellitus, hypertension, CVD, smoking history, and time on dialysis.
Fasting venous bloods were collected at 3 and 15 months posttransplant and stored at −80 °C until biochemical assessment. Plasma interleukin (IL) 18 (MBL, Nagoya, Japan), IL-12 (BD Biosciences, San Jose, California), and IL-6 (BD Biosciences) were measured by commercial enzyme-linked immunosorbent assay kit with a detection threshold of 12.5 pg/ml, 7.8pg/ml, and 4 pg/ml, respectively.
Arterial stiffness and wave reflections were measured noninvasively using SphgymoCor (North Ryde, Sydney, Australia) at 3 and 15 months post-transplant. Aortic PWV (as a measurement of arterial stiffness) was measured as the carotid-femoral PWV using the foot-to-foot method. Augmentation index (AI) adjusted for heart rate (AI × 75, as a measurement of wave reflections) was measured from the radial artery. Two operators who were not routinely involved in the care of renal transplant recipients obtained the measurements. All renal transplant recipients in our center have measurements of AI × 75 and PWV as part of their postkidney transplant routine standard of care.
clinical outcomes
Clinical outcomes of this study were obtained in all recipients at both 3 and 15 months posttransplant. Measurement of arterial stiffness (PWV) was the primary endpoint. Secondary endpoints were other measurements of CVD parameters, including wave reflections (AI × 75), blood pressure (average of 2 readings 30 minutes apart), and inflammatory cytokines, including IL-12, IL-18, and IL-6; measurements of metabolic parameters, including oral glucose tolerance test and homeostatic model assessment (HOMA) score in nondiabetics, lipid profile, and body mass index; measurements of graft outcomes including Modification Diet of Renal Disease-derived eGFR 12 and proteinuria; and measurements of safety and tolerability, including rejection (i.e., clinical indication biopsies) and adverse events.
statistics
Based on the paper by Seckinger et al., the sample size required to detect a difference of >0.5 m/s change in PWV between groups with α level of 0.05 and power of 80% was a minimum of 15 patients per group. 8 Non-normally distributed data were log transformed to normalize data. Results were expressed as frequency (percentage) for categorical data or as mean and 95% confidence interval (CI) or SD for continuous data. Comparisons of baseline characteristics between CNI-CNI and CNI-PSI groups were made by χ 2 test for categorical variables and analysis of variance and post hoc Bonferroni and Scheffe tests for continuous variables. Associations between CNI-CNI and CNI-PSI groups and other covariables and outcomes of interest were determined by univariable and multivariable generalized linear model. Only covariables with P < 0.2 in the univariable models were included in the multivariable models. Collinearity between covariables was examined using variance inflation factor (VIF), and a value ≥3 was considered suggestive of the presence of collinearity. Statistical evaluation was performed by SSPS version 10 statistical software program (SPSS, North Sydney, Australia). P < 0.05 was considered statistically significant.
results

Baseline characteristics at 3 months posttransplant
There were 50 and 17 RT recipients in the CNI-CNI and CNI-PSI groups, respectively. There was a similar proportion of diabetics (CNI-CNI = 8% vs. CNI-PSI = 6%) and recipients with prevalent CVD (CNI-CNI = 12% vs. CNI-PSI = 12%) in both groups. Compared with recipients in the CNI-CNI group, RT recipients in the CNI-PSI group were more likely to be men and to have received a live-donor kidney transplant, but this was not statistically significant (Table 1) .
cardiovascular parameters
Compared with RT recipients in the CNI-CNI group, recipients in the CNI-PSI group were associated with a significantly lower AI × 75 at 15 months posttransplant. There was a significant increase in AI × 75 between 3 and 15 months posttransplant in the CNI-CNI group but not in the CNI-PSI group (Table 2) . Covariables included in the multivariable model for AI × 75 at 15 months posttransplant included CNI-CNI and CNI-PSI groups, rejection, donor type, eGFR at 3 months posttransplant, systolic and diastolic blood pressure at 3 months posttransplant, and AI × 75 at 3 months posttransplant (all with P < 0.2 in the univariable models), but not BMI at 3 or 15 months posttransplant, age, sex, eGFR at 15 months posttransplant, change in eGFR between 3 and 15 months posttransplant, fasting cholesterol and triglyceride at 3 and 15 months posttransplant, diabetes, prevalent CVD, hypertension, current smoker, use of statin, number of antihypertensive medications, and systolic and diastolic blood pressure at 15 months posttransplant (all with P ≥ 0.2 in the univariable models). Only CNI-PSI group (coefficient = −5.14; 95% CI = −9.99 to −0.28; P = 0.04) and AI × 75 at 3 months posttransplant (coefficient = 0.44; 95% CI = 0.21-0.67; P < 0.01) were significantly associated with AI × 75 at 15 months posttransplant in the multivariable model (Table 3) . Within the CNI-CNI group, there was no association between different CNI (i.e., cyclosporin or tacrolimus) and AI × 75 at 15 months posttransplant.
There were no associations between CNI-CNI and CNI-PSI groups or any covariables with PWV or blood pressure at 3 and 15 months posttransplant.
Collinearity was not observed between any of the covariables, but specifically there was no collinearity between immunosuppressive regimens (VIF = 1.08), rejection (VIF = 1.09), age (VIF = 1.05), or sex (VIF = 1.15) and eGFR at 3 months posttransplant.
Metabolic parameters
Among nondiabetics, RT recipients in the CNI-PSI group had significantly lower fasting blood glucose at 15 months posttransplant than RT recipients in the CNI-CNI group. Recipients in the CNI-PSI group had significantly higher HOMA score at 3 months posttransplant than recipients in the CNI-CNI group, but HOMA score was similar at 15 months posttransplant. Fasting cholesterol was significantly reduced between 3 and 15 months posttransplant in the CNI-CNI group but remained stable in the CNI-PSI group. Numerically a greater proportion of recipients in the CNI-PSI group were maintained on lipid-lowering therapy at 15 months posttransplant compared with recipients in the CNI-CNI group (86% vs. 71%; P = 0.45), but this was not statistically significant (Table 2 ). Covariables included in the multivariable model for fasting blood glucose at 15 months posttransplant included CNI-CNI and CNI-PSI groups, eGFR at 3 months posttransplant, donor type, fasting blood glucose at 3 months posttransplant, HOMA at 3 and 15 months posttransplant (all with P < 0.2 in the univariable models), but not eGFR at 15 months posttransplant, rejection, age, sex, BMI at 3 or 15 months posttransplant, change in eGFR between 3 and 15 months posttransplant, prevalent CVD, hypertension, current smoker, systolic and diastolic blood pressure at 3 and 15 months posttransplant, and steroid dose at 3 and 15 months posttransplant or cumulative steroid dose (all with P ≥ 0.2 in the univariable models). Only CNI-PSI group (coefficient = −16.2; 95% CI = −14.4 to −18.0; P < 0.01), eGFR at 3 months posttransplant (coefficient = −0.014; 95% CI = −0.025 to −0.003; P = 0.017), and fasting blood glucose at 3 months posttransplant Abbreviations: ACE, angiotensin-converting enzyme; AI × 75, aortic augmentation index corrected for heart rate; ARB, angiotensin receptor blockers; CI, confidence interval; CNI, calcineurin-inhibitor; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HOMA, homeostatic model assessment; IL, interleukin; PSI, proliferation signal inhibitor; PWV, pulse wave velocity; SBP, systolic blood pressure. *P < 0.05 within groups.
(coefficient = 9.0; 95% CI = 1.8-14.4; P < 0.001) were significant associated with 15-month posttransplant fasting blood glucose in the multivariable model (Table 3) . Within the CNI-CNI group, there was no association between different CNI (cyclosporin vs. tacrolimus) and outcome.
inflammatory cytokines
Plasma levels of IL-6, IL-12, and IL-18 were similar between recipients in the CNI-CNI and CNI-PSI groups at 3 months posttransplant. Levels of IL-6 and IL-12 remained stable in both groups between 3 and 15 months posttransplant. The IL-18 level was significantly lower in the CNI-PSI group compared with the CNI-CNI group at 15 months posttransplant (262 vs. 527 pg/ml; P < 0.01) ( Table 2 ). Covariables included in the multivariable model for IL-18 at 15 months posttransplant included CNI-CNI and CNI-PSI groups, eGFR at 3 months posttransplant, recipient age, and IL-18 at 3 months posttransplant (all with P < 0.2 in the univariable models), but not eGFR at 15 months posttransplant, donor type, rejection, sex, BMI at 3 or 15 months posttransplant, fasting cholesterol or triglyceride at 3 and 15 months posttransplant, diabetes, prevalent CVD, hypertension, current smoker, use of statin therapy, number of antihypertensive medications, and systolic and diastolic blood pressure at 3 and 15 months posttransplant (all with P ≥ 0.2 in the univariable models). Only CNI-PSI groups (coefficient = −229.16; 95% CI = −343.94 to −114.38; P < 0.01) and IL-18 at 3 months posttransplant (coefficient = 0.31; 95% CI = 0.10-0.53; P< 0.01) were significantly associated with 15-month posttransplant IL-18 levels in the multivariable model (Table 3) . Within the CNI-CNI group, there was no association between different CNI (cyclosporin vs. tacrolimus) and outcome.
graft outcome
Numerically a greater proportion of recipients in the CNI-PSI group than in the CNI-CNI group had experienced acute rejection (all Banff I or II rejections with median time to rejection 7 months; range = 4-10 months; all occurred before conversion from CNI to PSI), but this was not statistically significant (11.8% vs 2.0%; χ 2 P = 0.09). Proteinuria was not statistically different in both groups at 3 and 15 months posttransplant, and there was a nonsignificant trend toward lower spot urine Table 3 . Association between immunosuppressive regimens and aortic augmentation index corrected for heart rate (AI × 75), interleukin 18 (IL-18), estimated glomerular filtration rate (eGFR), and fasting blood glucose at 15 months posttransplant in multivariable analyses. Abbreviations: AI × 75, aortic augmentation index corrected for heart rate; BSL, blood glucose; CNI, calcineurin-inhibitor; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; IL, interleukin; PSI, proliferation signal inhibitor; SBP, systolic blood pressure.
Only the coefficients of covariates in the multivariate models are shown. This observational study has shown that the elimination of CNI for PSI in RT recipients may be associated with improvement in several surrogate markers of CVD, including a reduction in IL-18 and stabilization of AI × 75, independent of age, sex, and graft function. Despite the improvement in rejection rates and shortand medium-term graft survival over the last 2 decades, death with functioning graft remains one of the most common causes of late graft loss in renal transplantation. Because CVD-related mortality contributes up to 15% of death with functioning graft, 3 there is now a greater focus on the prevention of CVD, and studies exploring the differential impact of immunosuppressive agents on CVD risk are critical in the longer-term management of RT recipients.
Surrogate markers of CVD, including aortic stiffness and central wave reflections, measured by PWV and AI × 75, respectively, have been shown to independently predict CVD events and/or all-cause mortality in patients with chronic kidney disease and RT recipients. 13, 14 Three randomized studies in RT recipients demonstrated that CNI elimination for PSI was associated with improvement in surrogate markers of CVD, including reduction in left ventricular hypertrophy and stabilization of PWV. 8, 9 Similarly, our study has demonstrated that CNI elimination for PSI was associated with stable AI × 75 and PWV between 3 and 15 months posttransplant, independent of traditional Framingham CVD risk factors, whereas the continuation with CNI was associated with a significant increase in AI × 75 but not PWV over time. It is plausible that the lower baseline eGFR in the CNI-PSI recipients may have, in part, explained the lack of difference in PWV between the CNI-CNI and CNI-PSI recipients, as PWV has been demonstrated to be inversely associated with GFR. 15 In addition, previous studies have demonstrated in RT recipients that cyclosporine may be associated with increased arterial stiffness and higher PWV or AI × 75 compared with tacrolimus, but this remains debatable and was not observed in our study. 16 IL-12 and IL-18 are proinflammatory T-helper 1 cytokines released by antigen-presenting cells, which are implicated in the pathogenesis of atherosclerosis and CVD in the general population. 17, 18 A recent study in RT recipients suggests that PSI, but not CNI, was capable of inhibiting the production of T-helper 1 cytokines by ex vivo isolated peripheral blood mononuclear cells. 10 This finding was corroborated by Ko et al., who demonstrated in a mouse model that sirolimus, but not cyclosporine, was able to inhibit IL-18 production by dendritic cells in vitro and in vivo. 19 Similarly, our study has demonstrated that RT recipients in the CNI-PSI group had significantly lower IL-18 levels than RT recipients in the CNI-CNI group. The lack of difference in IL-12 levels between groups may reflect the high proportion of recipients in both groups being maintained on statin therapy, which has been shown to suppress production of IL-12 from peripheral blood mononuclear cells in vitro. 20 However, we found no association between IL-12 or IL-18 and PWV or AI × 75, perhaps because of the small number of recipients in this study.
Consistent with recently published studies, our study demonstrated that the switch from CNI to PSI was associated with almost a 20 ml/min improvement in eGFR between 3 and 15 months posttransplant. 21 In many of these studies, there was a high rate of discontinuation and rejection, the latter typically following CNI discontinuation and have no detrimental effect on graft function. Similarly, in our study, 12% of RT recipients maintained on PSI had experienced rejection after CNI withdrawal, but unlike in other studies, PSI was generally well tolerated with no discontinuation despite achieving target therapeutic levels.
The differential effect of CNI and PSI on glucose regulation remains unclear, with small single-center and registry studies suggesting that the use of PSI ± CNI was associated with a greater risk of abnormal glucose regulation. 11, 22 In our study, although there was no difference in the prevalence of abnormal glucose regulation between the CNI and PSI nondiabetic recipients, fasting blood glucose and HOMA score improved in PSI recipients, but this observation may reflect the small number of recipients in our study and should be investigated in a larger cohort.
There are several limitations to our study. This was an observational, single-center study with a small number of RT recipients available for analysis (potential for type 2 statistical error), and the possibility of indication bias cannot be excluded. Although we had collected data on the type and number of antihypertensive medications, we did not collect data on the dose of antihypertensive medications, which could have potentially affected AI × 75 and PWV. In addition, our study was powered only to detect differences in PWV and not other CVD parameters, and therefore the potential to draw conclusions about the associations between immunosuppressive regimens and other parameters are limited. A strength of this study is the complete data collection at the same time-points posttransplantation in both CNI-CNI and CNI-PSI recipients, which allowed a direct comparison between groups.
In conclusion, our study suggests that the elimination of CNI for PSI could potentially be associated with an improvement in several surrogate markers of CVD, but adequately powered, randomized, controlled studies are required to establish the causal relationship between immunosuppressive agents and CVD risk.
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